Fetal alcohol spectrum disorder and ADHD: Diagnostic implications and therapeutic consequences

Expert Review of Neurotherapeutics

Volumn 3, Issue 4, 2003, Pages 477-489

  O'Malley, Kieran D ^a   Storoz, Linda ^b  

^a Fetal Alcohol and Drug Unit   (United States)

^b Campbell Clinic   (Canada)

Author keywords

Attention deficit hyperactivity disorder; Fetal alcohol disorder

Indexed keywords

ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLORPRES; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FLUOXETINE; FLUVOXAMINE MALEATE; GUANFACINE; IMIPRAMINE; MELATONIN; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PEMOLINE MAGNESIUM; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRYPTOPHAN; UNCLASSIFIED DRUG;

AGGRESSION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; DEVELOPMENTAL DISORDER; DISEASE CLASSIFICATION; DOPAMINERGIC SYSTEM; FETAL ALCOHOL SPECTRUM DISORDER; FETAL ALCOHOL SYNDROME; GENETIC ANALYSIS; HUMAN; IMPULSIVENESS; MENTAL DISEASE; MENTAL INSTABILITY; NEUROPHARMACOLOGY; NORADRENERGIC SYSTEM; PRENATAL EXPOSURE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RAGE; REVIEW; SEIZURE; SLEEP DISORDER; SYMPTOMATOLOGY; TERATOGENICITY;

EID: 0042315252     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.4.477     Document Type: Review

References (97)

1. Lemoine P, Harousseau H, Borteyru JP. Les enfants de parents alcoholiques, anomalies observees a propos de 127 cas. Quest. Med. 21, 476-482 (1968).
2. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 2, 999-1001 (1973).
3. Streissguth AP, O'Malley KD. Neuropsychiatric implications and long-term consequences of fetal alcohol spectrum disorders. Sem. Clin. Neuropsychiatry 5, 177-189 (2000).
4. Kapp FME, O'Malley KD. Watch for the Rainbows. True Stories for Educators and Other Caregivers of Children With Fetal Alcohol Spectrum Disorders Frances. Kapp Education, Calgary, France (2001).
5. O'Malley KD, Streissguth AP. Clinical intervention and support for children aged zero to three with fetal alcohol spectrum disorder and their parents/ caregivers. In: Encyclopedia on Early Childhood Development. Centre of Excellence for Early Childhood Development Website, (2003). www.excellence-earlychildhood.ca. Most up-to-date paper reviewing the interventions and support for parents in population of children with fetal alcohol spectrum disorder under 5 years old.
6. Sampson PD, Streissguth AP, Bookstein FL et al. Incidence of fetal alcohol syndrome and the prevalence of alcohol related neurodevelopmental disorder. Teratology 56, 317-326 (1997).
7. Bookstein FL, Streissguth AP, Sampson PD et al. Corpus callosum shape and neuropsychological deficits in adult males with heavy fetal alcohol exposure. Alcohol Clin. Exp. Res. 23, 28A (1999).
8. Bookstein FL, Sampson PD, Streissguth AP, Connor PL. Geometric morphometrics of corpus callosum and subcortical structures in fetal alcohol affected brain. Teratology 4, 4-32 (2001).
9. Bookstein FL, Sampson PD, Connor PD, Streissguth AP. Midline corpus callosum is a neuroanatomical focus of fetal alcohol damage. Anat. Rec. (New Anat). 269, 162-174 (2002).
10. Li TK. Pharmacogenetics of response to alcohol and genes that influence alcohol drinking. J. Stud. Alcohol. 61, 5-12 (2000).
11. Jones KL. From Recognition to Responsibility. Josef Warkany, David Smith and the Fetal Alcohol Syndrome in the 21st Century, 2002. Warkany Lecture, Birth Defects Research (Part A). 67, 13-20 (2003).
12. O'Malley KD, Nanson J. Clinical implications of a link between fetal alcohol spectrum disorder and attention deficit hyperactivity disorder. Can. J. Psychiatry 47(4), 349-354, (2002). Recent article on the link between fetal alcohol spectrum disorderand attention deficit hyperactivity disorder.
13. Allen AJ. ADHD, phenotypes and pathophysiologies, advanced studies in medicine, Johns Hopkins University. 2(25), 906-909 (2002).
14. Amen DG. BrainPlace.com. ADD Subtype Checklist, the Amen Clinic for Behavioral Medicine (2002-2003).
15. Biederman J, Newcom J, Sprich S. Comorbidiry of attention deficit hyperactivity disorder with conduct, depression, anxiety and other disorders. Am. J. Psychiatry 148, 564 (1991).
16. O'Malley KD. Youth with comorbid disorders. In: The Handbook of Child and Adolescent Systems of Care. Pumriega AJ, Winters NC, (Eds). JosseyBass Publishers, CA, USA 276-315 (2003).
17. O'Connor DE, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ. Correlates of comorbid psychopathology in children with ADHD, J. Am. Acad. Child Adolesc. Psychiatry 42(2), 193-200 (2003).
18. Sulik KK, Johnson MC Webb MA. Fetal alcohol syndrome, embryogenesis in a mouse model. Science 214, 936-938 (1981).
19. Abel EL. Fetal Alcohol Syndrome and Fetal Alcohol Effects. Plenum Press, NY, USA (1984).
20. Nanson JL, Hiscock M. Attention deficits in children exposed to alcohol prenatally. Alcohol Clin. Exp. Res. 5, 656-661 (1991).
21. Driscoll CD, Streissguth AP, Riley EP. Prenatal alcohol exposure, comparability of effects in humans and animal models. Neurotoxicol. Teratol. 12, 231-237 (1991).
22. Hannigan JH, Randall S. Behavioral pharmacology in animals exposed prenatally to alcohol. In: Fetal Alcohol Syndrome, From Mechanism to Prevention. Abel EL (Ed.). CRC Press, NY, USA 191-213 (1996).
23. O'Malley KD, Hagerman RJ. Developing clinical practice guidelines for pharmacological interventions with alcohol-affected children. In: Intervening With Children Affected By Prenatal Alcohol Exposure. Proceedings of a special focus session of the interagency co-ordinating committee on fetal alcohol syndrome Chevy Chase (MD). Centers for Disease Control and Prevention (Eds). National Institute on Alcohol Abuse and Alcoholism, USA, 145-177 (1998). Best overview article on pharmacological management of children and adolescents with fetal alcohol spectrum disorder.
24. Streissguth AP, Barr HM, Kogan J, Bookstein FK. Understanding the occurrence of secondary disabilities in clients with fetal alcohol syndrome (FAS) and fetal alcohol effects (FAE). Final report to Centres for Disease Control and Prevention. Seattle, WA, University of Washington, Fetal Alcohol and Drug Unit. Tech. Report. 96(0), (1996).
25. Coggins TE, Friet T, Morgan T. Analyzing narrative productions in old school-age children and adolescents with fetal alcohol syndrome, an experimental tool for clinical applications. Clin. Ling. Phonet. 12, 221-236 (1998).
26. Glaser D. Child abuse and neglect and the brain - a review. J. Child Psy. Psychiatry 41, 97-116 (2000). Important current review paper on the interaction between child abuse/neglect and the brain. This is of critical importance to fetal alcohol spectrum disorder population.
27. Murray JP. Brain Structure Difference Linked to Disruptive Teens. Radiological Society of North America (RSNA). Paper presentation, 2nd December (2002).
28. Bauer LO, Hesselbrock VM. Brain maturation. Subtypes of conduct disorder, interactive effects on p300 amplitude and topography in male adolescents. J. Am. Acad. Child. Adolesc. Psychiatry 42(1), 106-115 (2003).
29. Giancola PR, Zeichner. A neuropsychological performance on tests of frontal lobe functioning and aggressive behavior in males. J. Abnorm. Psychol. 103, 832-835 (1994).
30. Goodman R. The relationship between normal variation in IQ and common childhood psychopathology, a clinical study. Eur. Child. Adolesc. Psychiat. 4, 187-196 (1995).
31. Stratton KR, Howe CJ, Battaglia FC. Fetal Alcohol Syndrome, Diagnosis, Epidemiology, Prevention and Treatment. Institute of Medicine, Medicine. National Academy Press, Washington DC, USA (1996). Institute of Medicine's definitive book which describes the fetal alcohol spectrum disorder subtypes.
32. Stromland KK, Pinazo-Duran MD. Optic nerve hypoplasia, comparative effects in children and rats exposed to alcohol during pregnancy. Teratology 50, 100-111, (1994).
33. Droesti IE. Nutritional factors underlying the expression of the fetal alcohol syndrome. In: Maternal Nutrition and Pregnancy Outcome. Keen CI, Bendich A, Willhite CC, (Eds). Ann. NY Acad. Sci. 678, 193-204 (1993). Most complete analysis of nutritional factors related to fetal alcohol spectrum disorder.
34. Tanner EM, Finn-Stevenson M. Nutrition and brain development, social policy implications, Am. J. Orthopsychiatry 72(2), 182-193 (2002).
35. Meyers A, Chawla N. Nutrition and the social, emotional and cognitive development of infants and young children zero to three. 21(1), 5-12 (2000).
36. Jameson S. Zinc status in pregnancy, the effect of zinc therapy on perinatal mortality, prematurity and placental ablation. In: Maternal Nutrition and Pregnancy Outcome. Keen CL, Bendich A, Willhite CC (Eds). Ann. NY Acad. Sci. 678, 178-192 (1993).
37. Arnold E, Jensen PS. Attention deficit disorders. In: Comprehensive Textbook of Psychiatry 6th Edition. Sadock, Yudofsky (Eds). 2, 2295-2310 (1995).
38. Pliszka SR, Mc Cracken JT, Maas JW. Catecholamines in attention deficit hyperactivity disorder. Current perspectives. J. Am. Acad. Child Adolesc. Psychiatry 35, 264-272 (1996).
39. Castellanos FX. Toward a pathophysiology of attention deficit/hyperactivity disorder. Clin. Paedtr. 3, 381-395 (1997).
40. Cyr M, Brown CS, Current drug therapy recommendations for the treatment of ADHD. Drugs 56, 215-222 (1998).
41. Stevenson J. Evidence for a genetic etiology in hyperactivity in children. Behav. Genet. 22, 337-343 (1992).
42. Cook EH, Stein MA, Krasowski MD. Association of attention deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56, 993-998 (1995).
43. Eaves LG, Silberg JL, Meyer JM. Genetics and developmental psychopathology 11, the main effects of gene and environment on behavioral problems in the Virginia twin study of adolescent behavioral development. J. Child Psychol. Psychiatry 38, 965-980 (1997).
44. Waldman I. Transmission disequilibrium tests of the association of DRD4 and DAT to symptoms of ADHD. Presented at World Congress of Psychiatric Genetics, Santa Fe, NM, USA (1997).
45. Druse MJ. Effects of maternal alcohol on the developing nervous system. In: Alcohol and Neurobiology, Brain Development and Hormone Regulation. Watson RR, (Ed.) CRC Press, NY, USA (1992).
46. Maneuffel MD. Neurotransmitter function, changes associated with in utero alcohol exposure. In: Fetal Alcohol Syndrome, From Mechanism to Prevention. Abel EL (Ed.). CRC Press, NY, USA, 171-189, (1997).
47. Tomkins DM, Sellers EM. Addiction and the brain, the role of neurotransmitters in the cause of drug dependence. CMAJ 20, 164(6), 817-821 (2001).
48. Rich D, Barone S. Critical periods of vulnerability for the developing nervous system, evidence from humans and animal models, environmental health perspectives. 108(Suppl. 3), 515-533 (2000).
49. Thompson RA, Nelson CA. Developmental science and the media. Am. Psychologist January, 5-15 (2001).
50. Hagerman RJ. Neurodevelopmental Disorders. Diagnosis and Treatment. Oxford University Press, NY, USA, Oxford, UK (1999).
51. O'Malley KD. Update on the role of medication in treating patients with FASD. Iceberg 10(3), 4-5 (2000).
52. Russell O. Seminars. In: The Psychiatry of Learning Disabilities. Royal College of Psychiatrists, USA, Chapters 4,5,8,10 and 20 (1997).
53. Synder J, Nanson J, Synder R, Block G. A study of stimulant medication in children with FAS. In: The Challenge of Fetal Alcohol Syndrome. Overcoming Secondary Disabilities. Streissguth AP, Kanter J (Eds). University of Washington Press, WA, USA, 64-77, (1997).
54. Oesterheld JR, Kofoed L, Tervo R, Fogas B, Wilson A, Fiechtner H. Effectiveness of methylphenidate in native american children with fetal alcohol syndrome and attention deficit/hyperactivity disorder, a controlled pilot study. J. Child Adol. Psychopharm. 8(1), 39-48 (1998).
55. O'Malley KD, Koplin B, Dohner VA. Psychostimulant clinical response in fetal alcohol syndrome. Can. J. Psychiatry 45(1), 90-91 (1999).
56. Coe JA, Sidders J, Riley K, Waltermire J, Hagerman RJ. A survey of medication response in children and adolescents with fetal alcohol syndrome. In: Nerodevelopmental Disorders. Hagerman RJ (Ed.). Oxford University Press, Oxford, USA (1999).
57. Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threomethylphenidate. J. Pharm. Exp. Ther. 241, 152-158 (1987).
58. Faraj BA, Israili ZH, Perel JM et al. Metabolism and disposition of methylphenidate- 14 C studies in man and animals. J. Pharm. Exp. Ther. 191, 535-547 (1974).
59. Srinivas NR, Quinn D, Hubbard JW, Midha KK. Enatioselective pharmacokinetics and pharmacodynamics of dl-threo methylphemdate in children with attention deficit hyperactivity disorder. Clin. Pharmacol. Ther. 52, 561-568 (1987).
60. Shaywitz SE, Hunt RD, Jatlow P et al. Psychopharmacology of attention deficit disorder. Pharmacokinetic, neuroendocrine and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 69, 688-694 (1982).
61. Gualtieri CT, Hicks RE, Patrick K, Schroeder SR, Breese GR. Clinical correlates of methylphenidate blood levels. Ther. Drug Monitor. 6, 379-392 (1984).
62. Sebrechts MM, Shaywitz SE, Shaywitz BA, Jatlow P, Anderson GA, Cohen DJ. Components of attention, methylphenidate dosage and blood levels in children with attention deficit disorder. Pediatrics 77, 222-228 (1986).
63. Winsberg BG, Kupietz SS, Sverd J, Hungund BL, Young NL. Methylphenidate oral dose plasma concentrations and behavioral response in children. Pharm. Bull 23, 107-110 (1982).
64. Kollins SH, Mac Donald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects, a review. Pharmacol. Biochem. Behav. 68, 611-627 (2001).
65. Challman TD, Lipksy JJ. Methylphenidate, its pharmacology and uses. Mayo Clin. Proc. 75, 711-721 (2000).
66. Klein-Schwartz W, Mc Grath J. Poison Center's experience with methylphenidate abuse in teens and preteens and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 43(3), 288-294 (2003).
67. Saunders L. The Absorption and Distribution of Drugs. Wllliam and Williams, Baltimore, MD, USA, 141-153 (1974).
68. Shiyama S, Soejima-Ohkuma T, Honda S et al. Major role of the CYP2C isoenzymes in deamination of amphetamine and bezphetamine, evidence for the quinidine-specific inhibition of the reactions catalyzed rabbit enzyme. Xenobiotica 27, 379-387 (1997).
69. Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamine and their 4-methoxylated derivatives. Xenobiotica 7, 719-732 (1999).
70. The Biochemical Basis of Neuropharmacology, 8th Edition. Cooper JR, Bloom FE, Roth RE (Eds). Oxford University Press, Oxford, UK (2003). Essential textbook reading for basic understanding of neuropharmacolgy, most recent edition.
71. Biederman J, Loez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention deficit hyperactivity disorder. Pediatrics 110(2), 258-273 (2002a).
72. Tulloch SJ Zhang Y, Mc Lean A, Wolf KN SLI 381 (Adderall XR), a two component, extended-release formulation of mixed amphetamine salts, bioavailability of three test formulations and comparison of fasted, fed and sprinkled administration. Pharmacotherapy 11, 1405-1415 (2002).
73. Kractochvil CJ. New ADHD treatment options on the horizon. Adv. Stud. Med. 2(25), 915-918 (2002).
74. Eli Lilly Co., IN, USA. Strattera package information (2002).
75. O'Malley KD. Medication therapy's role for FAS. Iceberg. 7(4), 1,3-4 (1997).
76. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, (DSM IV), American Psychiatric Association, Washington DC, USA, 74-85 (1994).
77. American Academy of Pediatrics (AAP). Clinical Practice Guidelines, Diagnosis and evaluation of the child with attention deficit hyperactivity disorder. Pediatrics 105(5), 1158-1170 (2000). Current American Academy of Pediatrics guidelines on diagnosis of attention deficit hyperactivity disorder.
78. Biederman J. Practical considerations in stimulant drug selection for the attention-deficit hyperactivity disorder patient efficacy, potency and titration. Today's Therapeutic Trends 20 (4), 311-328 (2002b). Recent clinical review article on pharmacotherapy of attention deficit hyperactivity disorder by a well-respected international expert.
79. Zero to Three. National Center for Infants, Toddlers and Families. 5th Printing, 734 15th Street NW, Suite 1000, Washington, DC USA, 20005-1013 (1999).
80. Thomas A, Chess S. Temperament and Development. Brunner/Mazel, NY, USA (1977).
81. O'Malley KD. Temperament and attachment issues in fetal alcohol spectrum disorder, children's mental health - a systems of care approach. Paper presentation, AACAP, Portland, OR, USA, August 3rd (2001).
82. Havicek V, Childiaeva R, Chemick V. EEG frequency characteristics of sleep states in infants of alcoholic mothers. Neuropaediatrie 8, 360-373 (1977).
83. Storoz L. Personal communication, (2003).
84. Martin KR. Prenatal exposure to methamphetamine increases the vulnerabitity to the drug's neurotoxic effects in adult male mice. NIDA Notes 17(2), 11-12 (2001).
85. Mezzacappa E, Kindlon D, Earls F. Relations of age to cognitive and motivational elements of impulse control in boys with and without externalizing behavior problems. J. Abnor. Child Psychol. 27, 473-483 (1999).
86. Huggins JE, Connor PD, O'Malley KD, Barr HM, Streissguth AP. Suicidal behavior in fetal alcohol spectrum disorders (FASD). Proceedings of the 24th Scientific Meeting of the Research Society of Alcohol. Montreal, Canada, Abstract June (2001).
87. O'Malley KD, Barr H. Fetal alcohol syndrome and seizure disorder. Can. J. Psychiatry 43(10), 1051 (1998).
88. Barnard KE. Keys to Care-Giving. Self instructional video series. Available from NCAST Publications, University of Washington, Center for Human Development and Disabilities, Seattle, WA, USA, 98, 7195-7920 (1990).
89. Jirikowic T. Sensory integration for children with prenatal alcohol exposure. Iceberg 10(3), 1-2 (2000).
90. Pumariega AP, Fallon T. Pharmacotherapy in systems of care for mental health. In: The Handbook of Child and Adolescent Systems of Care. The New Community Psychiatry. Jossey-Bass, CA, USA, 120-148 (2003).
91. Koob GF, Weiss F. Neuropharmacology of cocaine and ethanol dependence. In: Recent Developments in Alcoholism. Galanter M, (Ed.). Plenum Press, NY, USA, 10, 201-233 (1992).
92. Tarter R, Vanyukov M, Dawes M, Blackson T, Mezzich A, Clark DB. Etiology of early onset substance use disorder, a maturational perspective. 11, 657-683 (1999).
93. Grant TM, Ernst CC, Streissguth AP. Intervention with high-risk alcohol and drug abusing mothers, 1. Administrative strategies of the Seattle Model of Paraprofessional Advocacy. J. Com. Psychol. 27, 1-18, (1999).
94. Ernst CC, Grant TM, Streissguth AP, Sampson PD. Intervention with high risk alcohol and drug abusing mothers, II Three year findings from the Seattle Model of Paraprofessional Advocacy. J. Com. Psychol. 27, 19-38 (1999).
95. Shire US, Inc., Florence, KY, USA. Adderall XR package insert (2001).
96. Celltech pharmaceuticals, Inc., Rochester, NY, USA. Metadate CD package insert (2002).
97. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Ritalin-LA package insert (2002).